Status:
COMPLETED
Examining the Function of Cs4 on Post-COVID-19 Disorders
Lead Sponsor:
The University of Hong Kong
Conditions:
Long COVID
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Cordyceps is a medicinal Chinese medicine. The benefits of cordyceps-related therapeutic action have been studied due to its anti-inflammation and immunomodulation features. Thus, Cordyceps may have e...
Detailed Description
Research Methodologies Participants Setting This is a waitlist-controlled trial to examine the therapeutic effect of Cs4 on long-COVID patients, which are divided into two groups. The study will be co...
Eligibility Criteria
Inclusion
- Male or female patients with age from 18 to 75 years old, who have been previously diagnosed with COVID-19 and recovered;
- The self-declared post-COVID-19 Functional Status scale should be at least over 1;
- The post-COVID symptoms have lasted at least 28 days after diagnosis;
- Currently not taking any other orally administered Chinese medicine;
- Negative COVID-19 antigen or nucleic acid test within 3 days prior to signing the consent form;
- Voluntary participation in this clinical study.
Exclusion
- Inability to read and/or write Chinese or English;
- Inability to communicate (e.g. with cognitive impairment) 3. Allergy to Cordyceps sinensis;
- 4\. Pregnant or lactating women; 5. Impaired hepatic or renal function.
Key Trial Info
Start Date :
April 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2024
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT06054438
Start Date
April 17 2023
End Date
March 31 2024
Last Update
July 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The School of Chinese Medicine, HKU
Hong Kong, China, 00000